AC IMMUNE
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. The Company designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins. AC Immune's two proprietary technology platforms create antibodies, small molecules and vaccines to address a broad spectrum of neurodegenerative indications
AC IMMUNE
Social Links:
Industry:
Biotechnology Pharmaceutical Therapeutics
Founded:
2003-01-01
Address:
Lausanne, Vaud, Switzerland
Country:
Switzerland
Website Url:
http://www.acimmune.com
Total Employee:
51+
Status:
Active
Contact:
+41 21 345 91 21
Email Addresses:
[email protected]
Total Funding:
167.49 M USD
Technology used in webpage:
Euro Pound Sterling Microsoft Japanese Yen Microsoft Azure Akamai Hosted Comodo SSL Comodo PositiveSSL Comodo PositiveSSL Wildcard Microsoft Azure France Central Region
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
AVEO Oncology
AVEO is a biopharmaceutical company that offers drug development strategies for targeted cancer therapeutics.
Imvax
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Inovio Pharmaceuticals
Inovio is a biotech company focusing on bringing to market DNA medicines for diseases associated with HPV, cancer, and infectious diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Biotechnology Value Fund
Biotechnology Value Fund investment in Post-IPO Equity - AC Immune
Redmile Group
Redmile Group investment in Post-IPO Equity - AC Immune
StemPoint Capital
StemPoint Capital investment in Post-IPO Equity - AC Immune
Avidity Partners
Avidity Partners investment in Post-IPO Equity - AC Immune
Dietmar Hopp
Dietmar Hopp investment in Series E - AC Immune
dievini Hopp Biotech Holding
dievini Hopp Biotech Holding investment in Series D - AC Immune
Key Employee Changes
| Date | New article |
|---|---|
| 2023-12-01 | AC Immune makes interim CFO Christopher Roberts permanent |
| 2023-07-26 | AC Immune names new chief medical officer |
Official Site Inspections
http://www.acimmune.com Semrush global rank: 3.61 M Semrush visits lastest month: 3.54 K
- Host name: cloudproxy10157.sucuri.net
- IP address: 192.124.249.157
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "AC Immune"
AC Immune - Crunchbase Company Profile & Funding
AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with three product candidates in clinical trials. …See details»
Investors | AC Immune SA
The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financial analysts.See details»
AC Immune SA – Swiss Biotech
AC Immune SA is a clinical-stage biopharma that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s, Parkinson’s, and NeuroOrphan indications. The Company has two clinically …See details»
AC Immune - Craft
Oct 29, 2024 AC Immune is a biopharmaceutical company developing therapeutics against Alzheimer´s disease and other conformational diseases. Its technology platforms allow to …See details»
AC Immune S.A. (ACIU-Q) Profile - The Globe and Mail
May 25, 2016 See the company profile for AC Immune S.A. (ACIU-Q) including business summary, industry/sector information, business summary, corporate governance, key executives.See details»
Who is AC Immune? A cutting-edge company with a …
AC Immune is a clinical-stage biopharmaceutical company emerging as a global leader in precision medicine to diagnose, treat and prevent neurodegenerative diseases. Since AC Immune’s foundation in 2003, our staff has developed …See details»
AC Immune - Overview, News & Similar companies | ZoomInfo.com
View AC Immune (www.acimmune.com) location in Vaud, Switzerland , revenue, industry and description. Find related and similar companies as well as employees by title and much more.See details»
AC Immune and Takeda Sign Exclusive Option and License …
May 13, 2024 “This agreement allows us to leverage the developmental expertise, strategic vision and financial capacity of an accomplished organization that has demonstrated its ability …See details»
Delivering breakthrough therapies for …
AC Immune’s leadership team combines a proven track record in entrepreneurial management and world-class scientific thought leadership. The team is committed to excellence and is passionate about delivering breakthrough …See details»
Interested in helping find a cure for neurodegenerative …
It is initiated by the nonprofit organization B Lab Switzerland. This program, which is unique at the European level, assists Swiss companies to measure their contributions to the Sustainable Development Goals (SDGs) and thus to …See details»
Our first- and best-in-class therapeutic & diagnostic candidates
We maximize the potential of our Morphomer® and SupraAntigen® technology platforms to bring innovative treatments to precisely defined patient populations. Our platforms deliver multiple …See details»
Takeda and AC Immune Announce Exclusive Option and License …
May 13, 2024 Takeda and AC Immune partner for ACI-24.060, an active immunotherapy targeting toxic forms of amyloid beta to potentially slow Alzheimer’s disease progression. …See details»
AC Immune SA Company Profile: Board of Directors, Capital …
Explore AC Immune SA company profile, including board of directors, capital structure, raw materials, finished goods, stock DNA, and contact details. Get a complete overview of …See details»
AC Immune SA Reports Q1 2025 Financial Results and Clinical ...
Apr 30, 2025 AC Immune reported Q1 2025 results, advancing its immunotherapy pipeline and maintaining strong financial resources through Q1 2027.See details»
AC Immune to Participate in Upcoming Investor Conferences
Mar 4, 2025 AC Immune to Participate in Upcoming Investor Conferences Lausanne, Switzerland, March 4, 2025 – AC Immune SA (NASDAQ: ACIU), a clinical-stage …See details»
AC Immune Partner LMI Progresses Tau PET Tracer PI-2620 into …
Sep 26, 2022 The organization strives to be a leader in the Molecular Imaging field by developing innovative products that improve early detection and characterization of chronic …See details»
AC Immune Reports First Quarter 2025 Financial Results and …
Mar 31, 2025 The Investor Relations website contains information about AC Immune SA's business for stockholders, potential investors, and financial analysts.See details»
HHS Takes Bold Step to Restore Public Trust in Vaccines by ...
5 days ago HHS removed the 17 sitting members of the Advisory Committee for Immunization Practices (ACIP) and will replace them with new members to restore public trust.See details»
AC Immune's Robust Pipeline focused on neurodegenerative …
Addressing Alzheimer’s, Parkinson’s and other neurodegenerative diseases AC IMMUNE’S ROBUST PIPELINE Based on our SupraAntigen® and Morphomer® technology platforms, we …See details»
Vaccine board purge stokes talk of CDC alternatives - Axios
3 days ago The big picture: The distress and lack of organization apparent in health circles on Tuesday was a sign that a new independent body that could act as a "shadow CDC" to truth …See details»